|
Lipka J,
Semmler-Behnke M, Wenk A, Burkhardt J,Aigner A, Kreyling W.
Biokinetic datasets of PEI F25-LMW complexed and non-complexed
32P-siRNA within different lung compartments.
Data Brief. 2016 Apr 1;7:1175-1178.
Schulze J, Hendrikx S, Schulz-Siegmund M, Aigner A.
Microparticulate poly(vinyl alcohol) hydrogel formulations for
embedding and controlled release of polyethylenimine (PEI)-based
nanoparticles.
Acta Biomater. 2016 Nov;45:210-222. doi: 10.1016/j.actbio.2016.08.056.
Aigner A,
Buesen R, Gant T, Gooderham N, Greim H, Hackermüller J,
Hubesch B, Laffont M, Marczylo E, Meister G, Petrick JS, Rasoulpour RJ,
Sauer UG, Schmidt K, Seitz H, Slack F, Sukata T, van der Vies SM,
Verhaert J, Witwer KW, Poole A.
Advancing the use of noncoding RNA in regulatory toxicology: Report of
an ECETOC workshop.
Regul Toxicol Pharmacol. 2016 Sep 20. pii: S0273-2300(16)30266-5. doi:
10.1016/j.yrtph.2016.09.018. [Epub ahead of print]
Gupta R, Arkatkar T, Keck J, Koundinya GK, Castillo K, Hobel S,
Chambers JP, Yu JJ, Guentzel MN,
Aigner A, Christenson LK, Arulanandam BP.
Antigen specific immune response in Chlamydia muridarum genital
infection is dependent on murine microRNAs-155 and -182.
Oncotarget. 2016 Aug 20. doi: 10.18632/oncotarget.11461. [Epub ahead of
print]
Ewe A, Panchal O, Pinnapireddy SR, Bakowsky
U, Przybylski S, Temme A,
Aigner A.
Liposome-polyethylenimine complexes (DPPC-PEI lipopolyplexes) for
therapeutic siRNA delivery in vivo.
Nanomedicine. 2016 Aug 20. pii: S1549-9634(16)30113-7. doi:
10.1016/j.nano.2016.08.005. [Epub ahead of print]
Matheis F, Heppt MV, Graf SA,
Düwell P, Kammerbauer C,
Aigner A, Besch R, Berking C.
A Bifunctional Approach of Immunostimulation and uPAR Inhibition Shows
Potent Antitumor Activity in Melanoma.
J Invest Dermatol. 2016 Aug 3. pii: S0022-202X(16)32234-5. doi:
10.1016/j.jid.2016.07.026. [Epub ahead of print]
Ewe A,
Aigner A.
Cationic Lipid-Coated Polyplexes (Lipopolyplexes) for DNA and Small RNA
Delivery.
Methods Mol Biol. 2016;1445:187-200. doi: 10.1007/978-1-4939-3718-9_12.
Ewe A, Höbel S, Heine C, Merz L, Kallendrusch S, Bechmann I,
Merz F, Franke H,
Aigner A.
Optimized polyethylenimine (PEI)-based nanoparticles for siRNA
delivery, analyzed in vitro and in an ex vivo tumor tissue slice
culture model.
Drug Deliv Transl Res. 2016 Jun 22. [Epub ahead of print]
Nörenberg W, Plötz T,
Sobottka H, Chubanov V, Mittermeier L, Kalwa H, Aigner A, Schaefer
M.
TRPM7 is a molecular substrate of ATP-evoked P2X7-like currents in
tumor cells.
J Gen Physiol. 2016 Jun;147(6):467-83. doi: 10.1085/jgp.201611595
Koerfer J, Kallendrusch S, Merz F, Wittekind
C, Kubick C, Kassahun WT, Schumacher G, Moebius C, Gaßler N,
Schopow N, Geister D, Wiechmann V, Weimann A, Eckmann C, Aigner A, Bechmann
I, Lordick F
Organotypic slice cultures of human gastric and esophagogastric
junction cancer.
Cancer Med. 2016 Apr 12. doi: 10.1002/cam4.720. [Epub ahead of print]
Ewe A, Przybylski S, Burkhardt J, Janke A,
Appelhans D,
Aigner A.
A novel tyrosine-modified low molecular weight polyethylenimine (P10Y)
for efficient siRNA delivery in vitro and in vivo.
J Control Release. 2016 May 28;230:13-25. doi:
10.1016/j.jconrel.2016.03.034
Aigner
A, Fischer D.
Nanoparticle-mediated delivery of small RNA molecules in tumor therapy.
Pharmazie. 2016 Jan;71(1):27-34.
Lipka J, Semmler-Behnke M, Wenk A, Burkhardt
J, Aigner A,
Kreyling W.
Biokinetic studies of non-complexed siRNA versus nano-sized PEI
F25-LMW/siRNA polyplexes following intratracheal instillation into mice.
Int J Pharm. 2016 Mar 16;500(1-2):227-35. doi:
10.1016/j.ijpharm.2016.01.038.
Brinkman DJ, Tichelaar J, Schutte T, Benemei
S, Böttiger Y, Chamontin B, Christiaens T, Likic R,
Mačiulaitis R, Marandi T, Monteiro EC, Papaioannidou P, Pers YM, Pontes
C, Raskovic A,
Regenthal R,
Sanz EJ, Tamba BI, Wilson K, de Vries TP, Richir MC, van Agtmael MA
Essential Competencies in Prescribing: A First European Cross-Sectional
Study Among 895 Final-Year Medical Students.
Clin Pharmacol Ther. 2016 Sep 20. doi: 10.1002/cpt.521. [Epub ahead of
print]
Rae CL, Nombela C, Rodríguez PV,
Ye Z, Hughes LE, Jones PS, Ham T, Rittman T, Coyle-Gilchrist I,
Regenthal R,
Sahakian BJ, Barker RA, Robbins TW, Rowe JB.
Atomoxetine restores the response inhibition network in Parkinson's
disease.
Brain. 2016 Aug;139(Pt 8):2235-48. doi: 10.1093/brain/aww138.
Hinderberger P, Rullmann M, Drabe M,
Luthardt J, Becker GA, Blüher M,
Regenthal R,
Sabri O, Hesse S.
The effect of serum BDNF levels on central serotonin transporter
availability in obese versus non-obese adults: A [(11)C]DASB positron
emission tomography study.
Neuropharmacology. 2016 Nov;110(Pt A):530-6. doi:
10.1016/j.neuropharm.2016.04.030.
Ye Z, Rae CL, Nombela C, Ham T, Rittman T,
Jones PS, Rodríguez PV, Coyle-Gilchrist I,
Regenthal R,
Altena E, Housden CR, Maxwell H, Sahakian BJ, Barker RA, Robbins TW,
Rowe JB.
Predicting beneficial effects of atomoxetine and citalopram on response
inhibition in Parkinson's disease with clinical and neuroimaging
measures.
Hum Brain Mapp. 2016 Mar;37(3):1026-37. doi: 10.1002/hbm.23087.
Hesse S, Rullmann M, Luthardt J, Winter K, Hankir MK, Becker GA, Zientek F, Reissig G,
Regenthal R, Drabe M,
Schinke C, Bresch A, Arelin K, Lobsien D, Patt M, Meyer PM, Fasshauer
M, Fenske WK, Blüher M, Stumvoll M, Sabri O.
Central serotonin transporter availability in highly obese individuals
compared with non-obese controls: A [(11)C] DASB positron emission
tomography study.
Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1096-104. doi: 10.1007/s00259-015-3243-y.
|